Differential effect of interleukin-10 on hepatocyte apoptosis.
Current data suggests that hepatocyte apoptosis is an essential feature contributing to several chronic liver diseases. It has been shown that IL-10 has diverse and potentially pleiotropic actions that suggest that it may have a direct effect on apoptosis. It has been established that NF-kappaB activation is essential to protect hepatocytes from apoptosis. The purpose of the present work is to evaluate the effect of the anti-inflammatory cytokine, IL-10 on the activation of NF-kappaB in primary cultured rat hepatocytes and hepatoblastoma (HepG2) cell line and explore its consequences on apoptosis. Apoptosis was induced by TNF-alpha and cicloheximide in HepG2 hepatoblastoma cells and by ethanol and a glutathione depletor in primary cultured rat hepatocytes. NF-kappaB activation was determined by EMSA. IL-10 increased ethanol induced apoptosis in primary culture rat hepatocytes (28%). These effects were enhanced when the cells were pre-treated with IL-10 under conditions of oxidative stress (glutathione depletion). The effects of IL-10 on primary cultured hepatocytes were independent of NF-kappaB activation. When apoptosis was induced by cicloheximide and TNF-alpha in hepatoblastoma cells, pretreatment with IL-10 was accompanied by a decrease of 38% in apoptosis. IL-10 did not have any effect on the signaling cascade of apoptosis but caused a significant increase in NF-kappaB activation. When NF-kappaB activation was inhibited by sulfazalazine the decrease in apoptosis was reversed. The present study demonstrates the importance of differential cell marking when trying to characterize the effects of cytokines in their contribution to liver cell apoptosis. The study provides insight into the mechanisms by which IL-10 affects apoptosis through a differential effect on NF-kappaB activation.
Santiago-Lomelí
Mariana
M
Departamento de Ciencias de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, México, D.F. México. marsantiagolom@yahoo.com.mx
Gómez-Quiroz
Luis E
LE
Ortíz-Ortega
Víctor M
VM
Kershenobich
David
D
Gutiérrez-Ruiz
Maria Concepción
MC
D000818:Animals; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D045744:Cell Line, Tumor; D002908:Chronic Disease; D003513:Cycloheximide / Q000494:pharmacology; D000431:Ethanol / Q000494:pharmacology; D018197:Hepatoblastoma / Q000473:pathology / Q000503:physiopathology*; D022781:Hepatocytes / Q000473:pathology / Q000502:physiology*; D006801:Humans; D016753:Interleukin-10 / Q000494:pharmacology*; D008107:Liver Diseases / Q000473:pathology / Q000503:physiopathology; D008113:Liver Neoplasms / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D016328:NF-kappa B / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D012997:Solvents / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D016328:NF-kappa B; D011500:Protein Synthesis Inhibitors; D012997:Solvents; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D000431:Ethanol; D003513:Cycloheximide